Ann: Letter to Shareholders, page-23

A big drop on small volume, but larger volume has followed to sit in the sell queue.

The Chairman's promise to shareholders they are diligently working on new products to compliment the BCD (blood collection device) was obviously BS.

The financial statements show zero dollars spent on R&D.

I looked at previous announcements and the posturing of progress and exciting years ahead is embarrassing.

I understand the ASX is a business and collect tens of thousands in listing fees from each coy, but they are the regulators and should do more to decipher 'well intentioned ideas' and structured businesses with a pipeline.

A large percentage of listed companies wouldn't make it through the shark tank pitch, yet they are able to acquire ticker codes and announce yearly Chairman Letters spruiking a commitment to success.